MK-677
Also known as: Ibutamoren, Nutrobal
Brand names: Ibutamoren, Nutrobal
MK-677 (Ibutamoren) is an orally-active growth hormone secretagogue that mimics the action of ghrelin. Unlike peptide injections, it is taken orally and has a long half-life allowing once-daily dosing. Clinical trials have demonstrated increases in GH and IGF-1 levels, improved bone density, and enhanced lean body mass. Despite reaching Phase 2 trials, it was never approved by the FDA. Note: MK-677 is technically not a peptide but an oral non-peptide compound; it is included here because it is commonly grouped with peptide therapies.
Oral growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release
| Parameter | Detail |
|---|---|
| Administration | Oral |
| Typical Dose | 10-25mg daily |
| Frequency | Daily |
Common Side Effects
Serious Side Effects
- Active cancer
- Pregnancy
- Children
- Diabetes
- WADA prohibited substance
Evidence Quality
Clinical Trial Phase
Phase 2
| Peptide | Monthly Cost | FDA Status |
|---|---|---|
| MK-677 | $50 - $100/mo | Phase 2 |
| CJC-1295 | $35 - $70/mo | Category 2 (pending reclassification) |
| Ipamorelin | $35 - $70/mo | Category 2 (pending reclassification) |
| GHRP-6 | $35 - $70/mo | Not submitted |
| Sermorelin | $150 - $350/mo | Withdrawn (off-label use continues) |
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy or medication. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary.